| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02241135 | RNActive® Rabies Vaccine (CV7201) in Healthy Adults | PHASE1 | COMPLETED | 101 | — | — | Oct 1, 2013 | Feb 8, 2018 | Oct 29, 2018 | 1 | Germany |
The occurrence of AEs will be assessed by non-directive questioning of the subject at each visit. Further, AEs volunteered by the subject during or between visits - as subject diary card entries - or detected through observation, physical examination, laboratory test, or other assessments during the entire observation period, will be documented. Subjects will be instructed that they must immediately report any AEs, subjective complaints or objective changes in their well-being to the Investigator or the clinic personnel, regardless of the perceived relationship between the event and the test product. The Investigator is responsible for reporting all AEs in the eCRF that are observed or described by the subject, regardless of their relationship to the trial vaccine or their clinical significance.
| Arm | Type | Description |
|---|---|---|
| 80 µg CV7201 mRNA short | EXPERIMENTAL | Vaccination by injection on days 0, 7, 28. |
| 160µg CV7201 mRNA short | EXPERIMENTAL | Vaccination by injection on days 0, 7, 28. |
| 80 µg CV7201 mRNA long | EXPERIMENTAL | Vaccination by injection on days 0, 28, 56. |
| 160 µg CV7201 mRNA long | EXPERIMENTAL | Vaccination by injection on days 0, 28, 56. |
| 320 µg CV7201 mRNA long | EXPERIMENTAL | Vaccination by injection on days 0, 28, 56. |
| 640 µg CV7201 mRNA long | EXPERIMENTAL | Vaccination by injection on days 0, 28. |
| 200 µg CV7201 mRNA long | EXPERIMENTAL | Vaccination by injection on days 0, 28, 56. |
| 400 µg CV7201 mRNA long | EXPERIMENTAL | Vaccination by injection on days 0, 28, 56. |
| Name | Type | Description |
|---|---|---|
| CV7201 mRNA | BIOLOGICAL | CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein. |
Inclusion Criteria: 1. Healthy male and female volunteers aged 18 to 40 years inclusive 2. Compliant with protocol procedures and available for clinical follow-up through the last planned visit (V9) 3. Physical examination and laboratory results without clinically significant findings 4. Body Mass ...